{"id":"W4415940078","doi":"10.1016/j.annonc.2025.08.3223","title":"2607P Belzutifan for advanced clear cell renal cell carcinoma (ccRCC) after a PD-(L)1 inhibitor and ≥2 VEGFR-TKIs in LITESPARK-005","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Clear cell renal cell carcinoma; Clear cell; Discovery and development of mTOR inhibitors; Kidney cancer; Phases of clinical research; Renal cell carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000489129,0.0003515686,0.0009550952,0.0002261683,0.0003300706,0.000661588,0.0003389647,0.0004924642,0.003654898],"category_scores_gemma":[0.0004454867,0.0001751163,0.001161096,0.0003275287,0.0002706234,0.0006782577,0.0002605772,0.001876815,0.0007008775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067759,"about_ca_system_score_gemma":0.001180402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001984385,"about_ca_topic_score_gemma":0.009156315,"domain_scores_codex":[0.9997758,0.00003389283,0.00001848225,0.00004340548,0.00003137987,0.00009708232],"domain_scores_gemma":[0.9998092,0.00002670192,0.00002094143,0.00001510776,0.00001190934,0.0001160693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1875981,0.0102293,0.06472614,0.001298306,0.002460192,0.006297876,0.0003320056,0.005669669,0.02708519,0.003131402,0.03182506,0.6593468],"study_design_scores_gemma":[0.1133761,0.22918,0.4369481,0.0007818802,0.007089841,0.02098867,0.0006346114,0.02779295,0.02047292,0.007715163,0.1346921,0.0003276362],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9778782,0.006170065,0.001021433,0.001652689,0.0004191536,0.0002953986,0.001384143,0.000155517,0.01102325],"genre_scores_gemma":[0.9903123,0.001705394,0.0005728891,0.001237558,0.00009845884,0.0001111787,0.002826655,0.00002254484,0.003113001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003654898,"threshold_uncertainty_score":0.01222682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03004724296364463,"score_gpt":0.3343755571487835,"score_spread":0.3043283141851389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}